吲哚通过髓系细胞PFKFB3减轻饮食诱导的肝脏脂肪变性和炎症
该研究在137名受试者中发现循环吲哚水平与体重指数负相关,肥胖者吲哚水平显著低于瘦者且伴随肝脏脂肪含量增加。在高脂饮食喂养的C57BL/6J小鼠中,吲哚治疗显著减轻肝脏脂肪变性和炎症严重程度。机制上,吲哚以PFKFB3依赖方式刺激糖酵解关键调控基因表达并抑制巨噬细胞促炎活化,髓系细胞特异性PFKFB3缺失加剧高脂饮食诱导的NAFLD表型并削弱吲哚的保护作用。
要点
- 循环吲哚水平与BMI负相关,肥胖者显著低于瘦者且肝脏脂肪含量增加
- 吲哚减轻高脂饮食小鼠肝脏脂肪变性和炎症严重程度
- 吲哚通过髓系细胞PFKFB3依赖机制抑制巨噬细胞促炎活化
核心结论
- 吲哚与人类NAFLD相关,并能以髓系细胞PFKFB3依赖方式减轻小鼠饮食诱导的NAFLD表型。
- 吲哚模拟物和/或巨噬细胞特异性PFKFB3激活可能成为包括NAFLD在内的炎症相关疾病的预防和/或治疗途径。
研究设计与样本
- 人体队列研究纳入137名受试者,分析循环吲哚水平与体重指数及肝脏脂肪含量的关联。
- 动物实验使用高脂饮食喂养的C57BL/6J小鼠,给予吲哚治疗观察肝脏脂肪变性和炎症变化。
- 细胞实验检测吲哚对PFKFB3表达及巨噬细胞促炎活化的影响,并使用髓系细胞特异性PFKFB3缺失小鼠验证机制。
主要发现
- 在137名受试者中,循环吲哚水平与体重指数呈负相关。
- 肥胖受试者循环吲哚水平显著低于瘦受试者,并伴随肝脏脂肪含量增加。
- 高脂饮食喂养的C57BL/6J小鼠经吲哚治疗后,肝脏脂肪变性和炎症严重程度显著降低。
- 吲哚处理刺激PFKFB3表达,并以PFKFB3依赖方式抑制巨噬细胞促炎活化。
- 髓系细胞特异性PFKFB3缺失加剧高脂饮食诱导的肝脏脂肪变性和炎症,并削弱吲哚减轻NAFLD表型的作用。
关键数值与推荐
- 人体队列纳入137名受试者,循环吲哚水平与体重指数负相关。
- 肥胖受试者循环吲哚水平显著低于瘦受试者,且伴随肝脏脂肪含量增加。
- 高脂饮食喂养C57BL/6J小鼠中,吲哚治疗显著降低肝脏脂肪变性和炎症严重程度。
- 吲哚以PFKFB3依赖方式刺激PFKFB3表达并抑制巨噬细胞促炎活化。
- 髓系细胞特异性PFKFB3缺失加剧高脂饮食诱导的NAFLD表型并削弱吲哚的保护效应。
临床怎么用
- 吲哚水平与BMI及肝脏脂肪含量的关联提示其可能作为NAFLD的潜在生物标志物。
- 吲哚模拟物或巨噬细胞特异性PFKFB3激活可能成为NAFLD的预防或治疗策略。
- 髓系细胞PFKFB3通路是吲哚发挥抗NAFLD作用的关键机制靶点。
局限性
- 人体部分为观察性关联分析,不能证明吲哚与NAFLD的因果关系。
- 动物和细胞实验结论需进一步临床研究验证。
- 髓系细胞特异性PFKFB3缺失小鼠中吲哚效应被削弱但未完全消失,提示可能存在其他机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Indole is a microbiota metabolite that exerts anti-inflammatory responses. However, the relevance of indole to human non-alcoholic fatty liver disease (NAFLD) is not clear. It also remains largely unknown whether and how indole acts to protect against NAFLD. The present study sought to examine the association between the circulating levels of indole and liver fat content in human subjects and explore the mechanisms underlying indole actions in mice with diet-induced NAFLD. APPROACH AND RESULTS: In a cohort of 137 subjects, the circulating levels of indole were reversely correlated with body mass index. In addition, the circulating levels of indole in obese subjects were significantly lower than those in lean subjects and were accompanied with increased liver fat content. At the whole-animal level, treatment of high-fat diet (HFD)-fed C57BL/6J mice with indole caused significant decreases in the severity of hepatic steatosis and inflammation. In cultured cells, indole treatment stimulated the expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a master regulatory gene of glycolysis, and suppressed macrophage proinflammatory activation in a PFKFB3-dependent manner. Moreover, myeloid cell-specific PFKFB3 disruption exacerbated the severity of HFD-induced hepatic steatosis and inflammation and blunted the effect of indole on alleviating diet-induced NAFLD phenotype. CONCLUSIONS: Taken together, our results demonstrate that indole is relevant to human NAFLD and capable of alleviating diet-induced NAFLD phenotypes in mice in a myeloid cell PFKFB3-dependent manner. Therefore, indole mimetic and/or macrophage-specific PFKFB3 activation may be the viable preventive and/or therapeutic approaches for inflammation-associated diseases including NAFLD.
引用
- Ma L, Li H, Hu J, et al. Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3. Hepatology. 2020. PMID: 31953865. doi:10.1002/hep.31115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。